Faculty Directory

Jay Kramer

Jay Kramer

Associate Research Professor of Biochemistry and Molecular Medicine
Associate Research Professor of Medicine (Secondary)

Office Phone: 202-994-3539
Email: Email
Department: Biochemistry and Molecular Medicine

Education

  • BA, Northeastern University, 1976
  • MS, Lehigh University, 1979
  • PhD, Lehigh University, 1982

Biography

Jay was born in Brooklyn, raised in Valley Stream, N.Y., and graduated from V.S. Central High School in 1970. He received his Bachelors’ degree with honors in Biology from Northeastern University (NU, Boston, MA) in 1976, and participated in NU’s 5 year cooperative work-study program, working as a clinical lab technician for the Boston Medical Laboratory.  Jay attended graduate school and received his Masters’ of Science degree (1979) and Ph.D. (1982) in Molecular Biology from Lehigh University (Bethlehem, PA).  His Masters’ thesis was entitled "The Role of the Sarcolemma in Calcium Paradox and Ischemic Heart Failure: Effect of Taurine”, and Ph.D. dissertation was entitled "Effects of Taurine and Tolbutamide on the Normal and Failure-Subjected Heart".  Jay received his postdoctoral training in: cardiac biochemistry/biophysics at the Medical College of Virginia, Richmond, VA (1982-3); in cardiac biochemistry as part of the Cardiovascular Research Program at Oklahoma Medical Research Foundation, Oklahoma City, OK (1983-5); and in cardiac biochemistry/physiology as part of the Division of Experimental Medicine, Department of Medicine at The George Washington University Medical Center (GWUMC; Washington, D.C.,1985-6). Jay received the following honors and achievements: Dean’s List (each quarter, except one) from Northeastern University (NU); Bachelors’ with Honors from NU, elected member of The Phi Sigma Honor Society (Biology, NU); member of The Academy (Liberal Arts Honor Society, NU); received scholarship for Graduate Studies in Molecular Biology at Lehigh University; elected, Jaycee's "Outstanding Young Men Of America"; Marquis "Who's Who in Science and Engineering"; Marquis "Who's Who in The South and Southwest"; Marquis "Who's Who in America"; International Biographical Centre’s (Cambridge, England) Leading Scientists of the World; Madison’s “Who’s Who”, 2008-2009; and lifetime membership in Madison’s “Who’s Who; Biltmore’s 2011 Edition (national registry) of Who's Who Among Executives and Professionals; and Albert Nelson Marquis Lifetime Achievement Award Inductee, 2019. Jay received faculty promotion to Assistant Research Professor in The Department of Medicine (GWUMC) in 1986, and joined The Department of Physiology & Experimental Medicine (GWUMC) in 1998 as an Associate Research Professor. In 2004, Jay joined the Department of Biochemistry & Molecular Medicine (GWUMC), and currently holds the faculty rank of Associate Research Professor. He also holds an Adjunct Associate Professorship in The Division of Experimental Medicine, Department of Medicine, at GWUMC, is a faculty member of The Institute for Biomedical Sciences (graduate education/research) at GWUMC, and was acting director of The Electron Spin Resonance (ESR) Spectroscopy Suite (free radical detection) at GWUMC. Jay has given several formal lectures to medical students on muscle physiology (1986-1988) as part of the medical school PHYS #201 course for The Department of Physiology (GWUMC), and established independent research courses for credit for Biology and Medical students (IDIS 201). Jay periodically acts as research mentor to undergraduates, graduates, medical students, postdoctoral trainees, and medical residents seeking biomedical research experiences.  He is a current or former member of several GWUMC administrative- and research-related committees including: The Institutional Animal Care and Use Committee (IACUC, former member); past chairman of The IACUC Subcommittee on Animal Use/Care Non-Compliance Issues; former councilor and current member of The Basic Science Faculty Assembly; former member of The Development Committee of The Basic Science/Cardiovascular Center For Excellence; former member of The Multi-user Research (core) Facility Committee; and currently, the Ross Hall 4th Floor Warden, as part of the GWUMC Emergency Response Program. Jay was a major contributor to the departmental self - study document (research component & overall document organization) prepared for The Department of Physiology & Experimental Medicine prior to its in-house administrative review.  Jay was an active member of several professional societies including: The New York Academy of Sciences, Society for Experimental Biology and Medicine, Council on Basic Science of The American Heart Association, The Oxygen Society of Greater Washington, D.C., International Society for Free Radical Research, International Society for Heart Research, and The American Physiological Society.  Jay has contributed to 168 scientific research presentations and/or published abstracts to prestigious organizations (NIH, Federation of American Societies of Experimental Biology [FASEB], International Society for Heart Research, International Society for Free Radical Research, American Heart Association, Congress of The European Society of Cardiology, The Gordon Conference, The New York Academy of Sciences; various universities, and private corporations), and has authored or co-authored 72 peer-reviewed scientific articles. He was an ad hoc reviewer of scientific grant proposals for various sponsors (National Institutes Of Health/Heart, Lung, Blood; The Veterans Administration; The New York Academy of Sciences; The Jeffress Memorial Trust support for Scientific Research; Israel Science Foundation) as well as articles related to iron-mediated oxidative stress (free radicals) induced-tissue injury; cardiac ischemia/reperfusion injury; Mg-deficiency-induced inflammation; and antioxidant therapies.  Jay has been a principle or co-investigator on numerous funded scientific grant proposals focusing on experimental biomedical research. A selection of funded grant titles include: Free Radical Injury of Cardiovascular Cells and Membranes; Molecular Mechanisms of Cardiovascular Injury; Free Radical Injury of Ischemic Myocardium; Effect of Antiarrhythmic Drugs on Oxidative Injury of Myocytes; Free Radical Mechanisms and ACE Inhibitors; Magnesium-deficiency, Free Radicals and Cardiovascular Injury; Effects of Carvedilol on Free Radical-Induced Cardiomyopathy; The Anti-Radical Effects of Mg-salts against Endothelial Cell and Perfused Heart Injury; Substance P -Mediated Cardiovascular Inflammation; Oxidative Stress and Antioxidants in Iron Overload; EGFR Tyrosine Kinase Inhibition-Induced Cardiomyopathy Cardiomyopathy: Pro-oxidant Role of AZT and Mg-Deficiency; Protective Efficacy of Mg-Supplementation against NRTI-Induced Cardiac Toxicity; Iron Treatment Potentiates DOX-Induced Heart Failure and D-Propranolol Affords Protection; HAART-mediated Cardiovascular Toxicity in HIV-1 Tg Rats: Mg Protection; and Prevention of EGFR Inhibitor-Mediated Dermatitis, Cardiac Dysfunction and Genomic Alterations using Neurokinin-1 Receptor Blockade. The research of Jay and his colleagues has had, in many instances, a positive impact on the national and international scientific community. As a graduate student, Jay demonstrated that the amino acid, taurine, was protective to perfused hearts against calcium overload (the calcium paradox) induced-necrosis, and now taurine is commonly used in cardiomyocyte isolation buffers to limit calcium overload injury.  His more recent research endeavors have revealed the potential underlying contribution of oxidative stress in mechanisms of tissue injury associated with various disease conditions.  Using experimental animal models to simulate clinical conditions, his lab was among the first to: (i) demonstrate that oxygen free radical production (detected by Electron Spin Resonance [ESR] spectroscopy and spin trapping) in postischemic hearts was associated with the severity of the previous ischemic episode; (ii) show that the superoxide anion was the precursor to the hydroxyl radical which is generated during postischemic reperfusion; (iii) report endogenous oxygen- and carbon-centered free radical production in regionally-ischemic heart tissue; (iv) demonstrate circulating lipid free radical production in the regionally-ischemic/reperfused heart; (v) show that similar types of free radicals were also present in blood of patients following coronary bypass operations with cardioplegia. His lab was also the first to: (vi) recognize a link between neurogenic inflammation (substance P) in vivo and the enhanced susceptibility of hearts from Mg-restricted animals to postischemic stress; (vii) showed that pretreatment of experimental animals with non-overloading doses of iron can also enhance free radical production in postischemic hearts; (viii) introduce the concept that use of either acidic or ischemic pre-conditioning procedures to release redox-active tissue iron before imposing severe postischemic stress, may protect hearts against reperfusion injury; (ix) demonstrated that d-propranolol treatment affords cardioprotection against chronic iron-overload in animal models; (x) demonstrate with non-invasive echocardiography, the direct temporal relationships between: (a) dietary Mg-restriction; (b) chronic EGFR (epithelial growth factor receptor) Inhibitor treatment; and (c) chronic HAART (highly active anti-retroviral therapy) treatment, with the development of cardiac systolic and diastolic dysfunction in experimental animals; and (xi) the cardioprotective and anti-oxidative/anti-nitrosative effects of using either dietary Mg-supplementation or neurokinin-1 (substance P) receptor inhibitors in these experimental models. 
 

Grants

Grants Awarded (Funded) or PendingOf the 121 submitted funding opportunities, the following received funding or are pending:
1. Title of Grant: "Free radical injury of cardiovascular cells and membranes"
Funding Agency: NIH grant # RO1HL36419
Dates of Award: 1983-1986.
Yearly Direct Costs of Award: $250,000
Role (PI, Co-PI, etc.): Co-I
% Effort: 20%
2. Title of Grant: "Mechanisms of injury of myocardial membranes” 
Funding Agency: NIH grant # RO1HL36418
Dates of Award: 1984-1987.
Yearly Direct Costs of Award: $250,000
Role (PI, Co-PI, etc.): Co-I
% Effort: 20%
3. Title of Grant: "Mechanisms of injury of myocardial membranes” 
Funding Agency: NIH grant # RO1HL36418
Dates of Award: 1987-1992.
Yearly Direct Costs of Award: $250,000
Role (PI, Co-PI, etc.): Co-I
% Effort: 20%
 
4. Title of Grant: Subproject G.C. - Mass Spectroscopy Unit Instrument grant”
Funding Agency: NIH-1-S15-HL39507 (NIH Shared Instrument Grant DRR-BRS,)
Dates of Award: 7/87-6/88
Yearly Direct Costs of Award: $43,700
Role (PI, Co-PI, etc.): Co-I
% Effort: 20%
5. Title of Grant: "Free radical injury of cardiovascular cells"
Funding Agency: NIH grant # RO1HL36419
Dates of Award: 1987-rolled over into funded program project grant.
Yearly Direct Costs of Award: $250,000
Role (PI, Co-PI, etc.): Co-I
% Effort: 20%
6. Title of Grant: "Free radical injury of cardiovascular membranes"
Funding Agency: Project 1-A of NIH Program Project Grant # 1-PO1-HL38079
Dates of Award: 1987-1992.
Yearly Direct Costs of Award: $250,000
Role (PI, Co-PI, etc.): Co-I
% Effort: 20%
7. Title of Grant: "Free Radical Injury of Ischemic Myocardium "
Funding Agency: Project 1-B of NIH Program Project Grant # 1-PO1-HL38079
Dates of Award: 1987-1990.
Yearly Direct Costs of Award: $50,000
Role (PI, Co-PI, etc.): PI
% Effort: 20%
8. Title of Grant: "The Role of Amino Acids In Recovery from Myocardial Ischemia"
Funding Agency: American Heart Association
Dates of Award: 1988 - 1989.
Yearly Direct Costs of Award: $18,000
Role (PI, Co-PI, etc.): Co-PI
% Effort: 10%
9. Title of Grant: "Effect of antiarrhythmic drugs on oxidative injury of myocytes "
Funding Agency: American Heart Association grant-in-aid
Dates of Award: 1987 - 1988.
Yearly Direct Costs of Award: $20,000
Role (PI, Co-PI, etc.): Co-I
% Effort: 10%
10. Title of Grant: "Does epidural/general anesthesia induce myocardial ischemia in stable coronary artery stenosis ".
Funding Agency: American Heart Association grant-in-aid
Dates of Award: 1991 - 1992.
Yearly Direct Costs of Award: $20,000.
Role (PI, Co-PI, etc.): Co-I/Consultant
% Effort: 10%
11. Title of Grant: "Free Radical Mechanisms and ACE Inhibitors: Cellular, Subcellular, Tissue and Whole Animal Studies ".
Funding Agency: Squibb and Sons Co.
Dates of Award: 1989.
Yearly Direct Costs of Award: $40,000.
Role (PI, Co-PI, etc.): Co-I/Consultant
% Effort: 10%
12. Title of Grant: "Free Radical Production In Post-Ischemic Myocardium ".
Funding Agency: NIH-2-S07-RR05359-25
Dates of Award: 1987 - 1988.
Yearly Direct Costs of Award: $12,000.
Role (PI, Co-PI, etc.): PI
% Effort: 20%
13. Title of Grant: "Studies of the Post-Ischemic Rat Heart: Effects of Nicardipine ".
Funding Agency: Syntex Co.
Dates of Award: 1988 - 1989.
Yearly Direct Costs of Award: $21,200.
Role (PI, Co-PI, etc.): Co-PI
% Effort: 20%
14. Title of Grant: Subproject "Cellular Mechanisms Of Cardiovascular Injury ".
Funding Agency: NIH Shared Instrument Grant DRR-BRS, Meridian Interactive Laser            Cytometer.
Dates of Award: 1989.
Yearly Direct Costs of Award: $217,550 purchase price of ACAS 570 Interactive Laser Cytometer.
Role (PI, Co-PI, etc.): Co-I
% Effort: 10%
15. Title of Grant: "Mechanisms of Injury of Myocardial Membranes and Cells ".
Funding Agency: NIH competitive grant renewal # 2-RO1-HL36418.
Dates of Award: 1992-1997.
Yearly Direct Costs of Award: $250,000.
Role (PI, Co-PI, etc.): Co-I
% Effort: 20%
16. Title of Grant: "Effect of Lacidipine on Mechanical, Hemodynamic and Free Radical Generating Properties of Post-Ischemic Rat Hearts ".
Funding Agency: Glaxo International.
Dates of Award: 1991 - 1992.
Yearly Direct Costs of Award: $55,500.
Role (PI, Co-PI, etc.): Co-PI
% Effort: 20%
17. Title of Grant: "Magnesium-Deficiency, Free Radicals and Cardiovascular Injury ".
Funding Agency: NIH grant 1-RO1-HL49232.
Dates of Award: 1992-1995.
Yearly Direct Costs of Award: $250,000.
Role (PI, Co-PI, etc.): Co-I
% Effort: 20%
18. Title of Grant: "Effects of Carvedilol on Free Radical-Induced Cardiomyopathy ".
Funding Agency: Smith-Kline-Beecham Pharmaceuticals.
Dates of Award: 1993.
Yearly Direct Costs of Award: $10,000.
Role (PI, Co-PI, etc.): Co-PI
% Effort: 20%
19. Title of Grant:Pro-oxidant stress and myocardial pathobiology ".
Funding Agency: Saudi Arabian Research Training Initiative (KFSH/RC)
Dates of Award: 1994 - 1995.
Yearly Direct Costs of Award: $511,665.
Role (PI, Co-PI, etc.): Subproject PI/Mentor
% Effort: 10%
20. Title of Grant:Cardiovascular studies with carvedilol and two metabolites ".
Funding Agency: Boehringer Mannheim
Dates of Award: 1994 - 1995.
Yearly Direct Costs of Award: $23,251.
Role (PI, Co-PI, etc.): Co-PI
% Effort: 10%
21. Title of Grant: renewal Cardiovascular studies with carvedilol and two metabolites ".
Funding Agency: Boehringer Mannheim
Dates of Award: 1995 - 1996.
Yearly Direct Costs of Award: $43,551.
Role (PI, Co-PI, etc.): Co-PI
% Effort: 10%
22. Title of Grant:The anti-radical effects of Mg-salts against endothelial cell and perfused heart injury.".
Funding Agency: Fleming & Co (BM29664)
Dates of Award: 1995 - 1996.
Yearly Direct Costs of Award: $23,919.
Role (PI, Co-PI, etc.): Co-PI
% Effort: 15%
23. Title of Grant: SubprojectPostischemic oxidative protection provided by treatment in vivo with Roche compounds RS- 25560-197 and RS-47831-007".
Funding Agency: Roche Biosciences, Inc. 
Dates of Award: 1996 - 1997.
Yearly Direct Costs of Award: $50,000.
Role (PI, Co-PI, etc.): Co-PI
% Effort: 25%
24. Title of Grant:Mechanisms of Injury of Myocardial Membranes and Cells ".
Funding Agency: NIH competitive grant renewal # 2-RO1-HL36418
Dates of Award: 1996-2000.
Yearly Direct Costs of Award: $250,000.
Role (PI, Co-PI, etc.): Co-I
% Effort: 20%
25. Title of Grant:Substance P -Mediated Cardiovascular Inflammation ".
Funding Agency: NIH RO1 HL-062282
Dates of Award: 1999-2003.
Yearly Direct Costs of Award: $250,000.
Role (PI, Co-PI, etc.): Co-I
% Effort: 20%
26. Title of Grant:Oxidative Stress and Antioxidants in iron Overload ".
Funding Agency: NIH 1R01 HL066226
Dates of Award: 1999-2003.
Yearly Direct Costs of Award: $250,000.
Role (PI, Co-PI, etc.): Co-I
% Effort: 20%
27. Title of Grant:Cardiomyopathy: Pro-oxidant role of AZT and Mg-Deficiency ".
Funding Agency: NIH-R01-HL065718
Dates of Award: 2000-2005.
Yearly Direct Costs of Award: $250,000.
Role (PI, Co-PI, etc.): Co-I
% Effort: 20%
28. Title of Grant:Substance P -Mediated Cardiovascular Inflammation ".
Funding Agency: competitive grant renewal NIH-R01-HL065718
Dates of Award: 2002-2007.
Yearly Direct Costs of Award: $250,000.
Role (PI, Co-PI, etc.): Co-I
% Effort: 20%
29. Title of Grant:Cardiomyopathy: Pro-oxidant role of Zidovudine (AZT)".
Funding Agency: competitive grant renewal NIH-R01-HL065718
Dates of Award: 2003-2005.
Yearly Direct Costs of Award: $250,000.
Role (PI, Co-PI, etc.): Co-I
% Effort: 20%
30. Title of Grant:Oxidative Stress and Antioxidants in iron Overload ".
Funding Agency: NIH 1R01 HL066226
Dates of Award: 2007-2011.
Yearly Direct Costs of Award: $250,000.
Role (PI, Co-PI, etc.): Co-I
% Effort: 20%
31. Title of Grant:Protective Efficacy of Mg-Supplementation against NRTI-induced CardiacToxicity ".
Funding Agency: NIH R21 (NACCAM R21 AT003993)
Dates of Award: 2006-2008.
Yearly Direct Costs of Award: $275,000 for 2 yrs.
Role (PI, Co-PI, etc.): Co-PI
% Effort: 20%
32. Title of Grant:Iron Treatment Potentiates DOX-induced Heart Failure in Rats and D-Propranolol Affords Protection ".
Funding Agency: GWUMC Cheney Cardiovascular Institute
Dates of Award: 2008-2009.
Yearly Direct Costs of Award: $75,000.
Role (PI, Co-PI, etc.): PI
% Effort: 20%
33. Title of Grant:Substance P-Mediated Cardiovascular Inflammation ".
Funding Agency: NIH Director’s Bridge Funding of NIH RO1-HL-62282
Dates of Award: 2009-2010.
Yearly Direct Costs of Award: $250,000.
Role (PI, Co-PI, etc.): Co-I
% Effort: 20%
34. Title of Grant:Cardioprotective Efficacy of Mg-Supplementation during HAART Therapy".
Funding Agency: NIH RFA (R21 format)
Dates of Award: 2010-2012.
Yearly Direct Costs of Award: $275,000 for 2 yrs.
Role (PI, Co-PI, etc.): Co-I
% Effort: 20%
35. Title of Grant:Hypomagnesemia and Inflammation in Diabetic Patients ".
Funding Agency: The Dasman Diabetes Institute (Kuwait).
Dates of Award: 2013-2014.
Yearly Direct Costs of Award: $300,000.
Role (PI, Co-PI, etc.): Consultant
% Effort: as needed
36. Title of Grant:EGFR Tyrosine Kinase Inhibition - Induced Cardiomyopathy ".
Funding Agency: NIH R21
Dates of Award: 2011-2013.
Yearly Direct Costs of Award: $275,000 for 2 yrs.
Role (PI, Co-PI, etc.): Co-I
% Effort: 20%
37. Title of Grant:Aortic Valve Inflammation Due To Hypomagnesemia ".
Funding Agency: GWU Intramural Bridge Funding in support of submitted NIH RO1 HL114725.
Dates of Award: 2012-2013.
Yearly Direct Costs of Award: $71,083.
Role (PI, Co-PI, etc.): Co-I
% Effort: 20%
38. Title of Grant:Potential adjunct therapy for chelation during iron-overload ".
Funding Agency: GWU Intramural Bridge Funding in support of submitted NIH RO1
Dates of Award: 2013-2014.
Yearly Direct Costs of Award: $93,783.
Role (PI, Co-PI, etc.): Co-I
% Effort: 20%
39. Title of Grant:Project #3 – Establish a Biominerals Research Center ".
Funding Agency: Pending - Collaborative Research Program with the College of Medicine, Al-Imam Muhummad Ibn Saud Islamic University, Riyadh, Saudi Arabia and GWUMC.
Dates of Award: 2014-present.
Yearly Direct Costs of Award: $300,000.
Role (PI, Co-PI, etc.): Co-I (Project 3)
% Effort: 15%
40. Title of Grant: HAART-mediated Cardiovascular Toxicity in HIV-1 Tg Rats: Mg Protection ".
Funding Agency: Pending - NIH R21 grant
Dates of Award: 2014-2016.
Yearly Direct Costs of Award: $275,000 for 2 yrs.
Role (PI, Co-PI, etc.): Co-I   
% Effort: 20%
 
41. Title of Grant: “The Roles of Neurogenic Inflammation and Magnesium in Development of Type 2 Diabetes and Cardiovascular Oxidative Injury in Goto-Kakizaki Rats”
Funding Agency: Pending – KFAS (Kuwait Foundation for Advancement of Science)
Dates of Award: 2019-2023
Yearly Direct Costs of Award: ~ $ 200,000/yr x 3 years, pending
Role (PI, Co-PI, etc.): Co-I  
% Effort: 30-40%
 
42. Title of Grant: GWU Bridge Fund Support
Funding Agency: GWU (intermural)
Dates of Award: FY2014-15
Yearly Direct Costs of Award: $40,000
Role (PI, Co-PI, etc.): Co-I  
% Effort: 20%
 
43. Title of Grant: Prevention of EGFR Inhibitor-Mediated Renal-Cardiac Dysfunction and Genomic Alterations using Neurokinin-1 Receptor Blockade”
Funding Agency: McCormick Genomics and Proteomics Center, GWUMC, Funded
Dates of Award: 11/2016 to 11/2017
Yearly Direct Costs of Award: $15,000,
Role (PI, Co-PI, etc.): Co-PI  
% Effort: 20%
 
44. Title of Grant: “Prevention of EGFR Inhibitor-Mediated Dermatitis, Cardiac Dysfunction and Genomic Alterations using Neurokinin-1 Receptor Blockade”
Funding Agency: McCormick Genomics and Proteomics Center, GWUMC - Funded
Dates of Award: 11/2017 to 11/2018
Yearly Direct Costs of Award: $30,000
Role (PI, Co-PI, etc.): Co-PI  
% Effort: 20%
 
45. Title of Grant: “Proposal for Studies to Prevent Dermatitis due to Cancer Drug Therapy Funding Agency: Hoth Therapeutics, Inc.
Dates of Award: submitted 10/2018, pending
Yearly Direct Costs of Award: $167,682
Role (PI, Co-PI, etc.): Co-I  
% Effort: 30%
 
46. Title of Grant: “Prevention of Side Effects Due to Neurogenic Inflammation Caused by EGFR-targeted Anticancer Therapy”, in response to the Funding Opportunity PAR-16-275, Entitled “Serious Adverse Drug Reaction Research.”
Funding Agency: NIH
Dates of Award: 9/2019 – 8/2023, pending
Yearly Direct Costs of Award: $250,000 /yr direct x 4 yrs
Role (PI, Co-PI, etc.): Co-I  
% Effort: 40%
 
47. Title of Grant: Prevention of Cardiac and Cutaneous Side Effects Due to EGFR1/HER2-targeted Anticancer Therapy."
Funding Agency: DoD
Dates of Award: 9/2019 – 8/2023, pending; submitted March 28th, 2019
Yearly Direct Costs of Award: ($333,000/yr x 3 yrs direct), 50% effort.
Role (PI, Co-PI, etc.): Co-I  
% Effort: 50%.
 

 

Awards

Honors:

  • Graduate (B.A.) with Honors, Northeastern University, June 1976.
  • Dean’s List (each trimester, except one), Northeastern University, Fall 1970 – Spring 1976
  • Member, Phi Sigma Honor Society (Biology), Northeastern University, 1974-6.
  • Member, The Academy (Liberal Arts Honor Society), Northeastern University, 1974-6.
  • Scholarship (tuition) for Graduate Studies in Molecular Biology, Lehigh University, 1980-1981.
  • Elected, Jaycee's "Outstanding Young Men Of America", 1981,1982.
  • Elected, Marquis "Who's Who In Science And Engineering" 1992, 1997-1999, 2004-06.
  • Elected, Marquis "Who's Who In The South And Southwest" 1995.
  • Elected, Marquis "Who's Who In America" 1997-2006.
  • Principal Investigator/Study Designer for An Award-Winning Research Abstract/Presentation (#30), "The 1987 Free Radical Biology & Medicine Young Investigator Award" received by Dr. C. Arroyo
  • Principal Investigator/Study Designer for An Award-Nominated Research Abstract/Presentation (#76), "The 1997 Pharmacia & UpJohn Young Investigators Award", submitted by Dr. A. Komarov.
  •  Appointment, Adjunct Associate Professorship, Department of Physiology, The George Washington University Medical Center, 1991-1998.
  • Elected, International Biographical Centre’s (Cambridge, England), Leading Scientists of the World. 2005.
  • Elected, Madison’s “Who’s Who”, 2008-2009.
  • Elected, Madison’s “Who’s Who”, 2009-2010.
  • Selected top 50 professionals, Madison’s “Who’s Who”, 2010.
  • Selected as ‘Round Table’ Member, Madison’s “Who’s Who”, 2010.
  • Elected to Lifetime Membership, in Madison’s “Who’s Who”, 2011.
  • Elected, Biltmore’s 2011 Edition (national registry) of Who's Who Among Executives and Professionals.
  • Elected, Marquis Who's Who in Medicine and Healthcare, 2011.
  • Received Recognition from GWU President Knapp for pro-active performance (as floor warden) during the Ross Hall power failure, April 2011.
  • Recognition Certificate, 20 Years of Participation/Membership in The American Physiological Society, 2015
  • Selected, Marquis Who's Who Top (100) Scientist, 2019
  • Selected, Albert Nelson Marquis Lifetime Achievement Award Inductee, 2019
  • 2019 GWU Technology Commercialization Office (TCO) Innovation Competition. April 16th, 2019. Co-author of  an ‘Award Winning’ (2nd place) oral and poster presentation in Life Sciences Category ($5,000 prize).
     

Teaching

Courses Taught (Include role [course director, guest lecturer, etc.], numbers of lectures presented):

  • Lecturer in Muscle Physiology (teaching module of PHYS 201) to medical students, 2 x 2 hr. lectures, 1986, 1987, 1988.  GWUMC
 New Courses or Programs Developed:
  • Developed undergraduate research projects for academic credit (2 credit hours) in conjunction with the Chairman of The Department of Biology, GWU; 1993, 1994, 1996.
  • IDIS 201, fall 2000 semester, 1 credit hour course for medical student.

Research

Mechanism(s) through which dietary Mg-restricted diets mediate a pro-inflammatory/oxidative condition in rodent models, with emphasis on dietary threshold levels; The impact of dietary Mg-restricted diets on rat hearts subjected to ischemia / reperfusion (I/R) stress; Investigate the neuropeptide release mechanism exhibited by postischemic rat hearts as well as normally-perfused rat hearts exposed to varying perfusate Mg concentrations; The influence of chronic AZT treatment on tissue iron content in normal and Mg-restricted rodents; Assess the altered cardiotoxic effects of doxorubicin during iron overload and Mg-deficiency in rodents using non-invasive echocardiography; The involvement of endogenous iron redistribution as a mechanism to explain the beneficial effects of pre-conditioning on post-ischemically-stressed hearts; Determine the exogenous iron threshold level which predisposes hearts to I/R stress; Assess the acute and chronic antioxidant effects of d-propranolol and its analogs on I/R hearts from iron-loaded rats; and use echocardiography to investigate the potential benefits of: d-propranolol treatment during iron overload in rodents; neurokinin-1 (substance P) receptor blockade during diet- or EGFR inhibitor-induced Mg deficiency in rodents; and Mg-supplementation during chronic exposure to potentially toxic HAART drugs in normal and HIV-1 transgenic rodents.

Centers and Institutes

SMHS/SPHHS:

  • Member, Development Committee, Basic Science/Cardiovascular Center for Excellence, The George Washington University, 1992.
  • Member, Electron Microscopy Committee, The George Washington University, 1993-1994.
  • Member of The Multi-User Research (Core) Facility Committee, 2000-2003.
University:
  • Member, Institutional Animal Care and Use Committee (IACUC), The George Washington University Medical Center, 1988-2005; duties include reviewing IACUC research proposals for compliance with animal use and care policy, reviewing for scientific merit those proposals not receiving peer review, participating in inspections of ARF facility and investigator laboratories, contributing to/advising on in-house policy changes concerning animal use and care; contributing to the content of IACUC forms.  
  • Member, IACUC Subcommittee on Animal Use Training Program, The George Washington University, 1988.
  • Member, IACUC Subcommittee on Animal Use/Care compliance with PHS regulations, The George Washington University, 1994.
  • Member, Basic Science Faculty Assembly, The George Washington University, 1992-present.
  • Member, Institute for Biomedical Sciences (GW IBS), GWUMC, 1994-present.
  • Chairman (twice), IACUC Subcommittee on Animal Use/Care Non-Compliance Issues, The George Washington University, 2001, 2005. Duties included setting-up a formal investigation (interviews, written report, holding subcommittee meetings) and presenting findings/recommendations to the parent committee.
  • Chaired, the April 4th 2002 IACUC meeting and prepared meeting minutes which included issues concerning an Animal Use & Care Non-Compliance Issue.
  • Councilor, Basic Science Faculty Assembly Council, The George Washington University, 1992-1994; involved in early discussions and proposal which defined research areas of interest that comprised the subsequently established GWU Institute of Biomedical Sciences.
  • Alternate Ross Hall 4th Floor warden, as part of the GWUMC Emergency Response Program (3/04 – 6/07).
  • Formerly trained and received certification in CPR, AED and First Aid, as part of the GWUMC floor warden emergency response program, (3/05-4/05).
  • Ross Hall 4th Floor warden, as part of the GWUMC Emergency Response Program (7/07 –  present). Received recognition from GWU President Knapp for pro-active performance during the Ross Hall power failure, April 2011.
  • Formerly re-trained as part of the GWUMC floor warden emergency response program 6/3/14.
  • Participant in the April 20, 2018 Animal Research Facility Town Hall Meeting concerning ARF issues.
  • Member, nominated by my department Chair to serve on the Animal Research Facility Advisory Committee

Community Service

Service to Community (List agency, duration of participation, amount of effort and role on project.  Specify whether involvement was paid or unpaid, and whether your involvement was at regional, national or international level.):

Ad Hoc Reviewer of Scientific Journal Manuscripts and Grant Proposals
National and international recognition of my research in the areas of experimental postischemic reperfusion injury, free radical detection methodology, antioxidant pharmacology, Mg deficiency, Iron toxicity, and cardioprotective therapies, has led to numerous requests to act as an ad hoc reviewer of scientific manuscripts and/or proposals by several Professional Journals and Funding Agencies.  My participation was as an unpaid volunteer. On the average, a manuscript review takes 1-3 days and proposal reviews take 3-5 days. Most of my involvement (journal manuscript reviews) was at the national level, but I did act as a referee of a scientific proposal from a foreign country (Israel).
  • Journals: Circulation Research · Circulation · Free Radical Biology and Medicine · Proceedings of The Society For Experimental Medicine and Biology · American Journal Of Physiology · Journal of Molecular and Cellular Cardiology · Cardiovascular Research · Journal of Pharmacology and Experimental Therapeutics · Biochemical Pharmacology · Cardiovascular Drugs and Therapy · Pediatric Research. · Reviewer Of four manuscripts evolving from the Forum on Responsible Conduct in Biomedical Research, Published in PSEBM  · American Journal of Obstetrics and Gynecology · Cellular And Molecular Biology ·
  • Research & Symposium Proposals:  National Institutes Of Health/Heart, Lung, Blood (Research - RO1, PPG projects, Foggarty proposals) · Veterans Administration (Research) · New York Academy of Sciences (Symposium) · Review of Animal Care & Use Proposals for the GWUMC Institutional Animal Care & Use committee (IACUC) · Scientific Merit Review Of GWUMC Institutional Research Proposals · Jeffress Memorial Trust for Scientific Research · Israel Science Foundation ·
Participant/Attendee (3 days), at the FDA/NIH Joint Symposium entitled “Diabetes: Targeting Safe and Effective Prevention and Treatment.” Bethesda, MD, May 2004. Provided insight into current research interest areas and potential funding opportunities.
On a Local Community Basis, I participated in the following unpaid activities:
  • Fund raising for a local Virginia community travel youth soccer club.
  • Ran concession stand at local Virginia youth soccer tournament.
  • Acted as Field Marshall and/or Parking Coordinator at several tournament games for a local Virginia community travel soccer club.
  • Site coordinator during local Virginia youth soccer tournament.
  • Unpaid consultant to the Fairfax County (VA) Fire and Rescue Department on an issue concerning erroneous readings from a probe/device used to measure atmospheric oxygen in the presence of gaseous agents causing asphyxiation.
  • Member of a Virginia High School Academic/Athletic Booster Club, chaperon at school social events.
  • Attendee at Virginia High School, GWU and Univ of Maryland sporting events (mens soccer, basketball).
  • Fund raising/contributor to Local and Regional charitable organizations (SOME, Lupus, Purple Heart, AmVets, Big Brother/Big Sister, local fire/rescue squad)

Publications

View publications by this faculty member from January 1, 2013 - present

ElZohary, L. Weglicki, W.B., Chmielinska, J.J., Kramer, J.H., Mak, I.T. Mg-supplementation attenuated lipogenic and oxidative/nitrosative gene expression caused by combination antiviral therapy (cART) in HIV-1-transgenic rats. Plos One, 2019. PLOS ONE | https://doi.org/10.1371/journal.pone.0210107, 2019.

Kramer, J.H., Spurney, C.F., Chmielinska, J.J., Weglicki, W.B., Mak , I.T. Mg-supplementation protects against oxidative stress and cardiac dysfunction in chronic HAART-treated rats. In: HIV/AIDS: Oxidative Stress and Dietary Antioxidants. Eds. Preedy, V.R.A , and Watson, R. R., Academic Press, London, Part 2, Chapter 16, pp. 183-196, 2018.

Mak IT, Chmielinska JJ, Spurney CF, Weglicki WB, Kramer JH. Combination ART-induced oxidative/nitrosative stress, neurogenic inflammation and cardiac dysfunction in HIV-1 Transgenic (Tg) Rats: Protection by Mg-supplementation. International Journal of Molecular Sciences 19(8):2409-2426, 2018 (doi:10.3390/ijms19082409).

Mak, I.-T, Kramer, J.H., Chmielinska, J.J, Spurney, C.F., Weglicki, W.B. The EGFR TKI, erlotinib, causes hypomagnesemia, oxidative stress and cardiac dysfunction: attenuation by substance P-receptor blockade. J. Cardiovasc. Pharmacol. 65:54-61, 2015.

McCaffrey, T.A., Tziros, C., Lewis, J., Katz, R., Siegel, R., Weglicki,W., Kramer, J., Mak, I-T., Toma, I.,Chen, L., Benas, E., Lowitt, A., Rao, S., Witkins, L., Lian, Y., Lai, Y.,Yang, Z., Fu, S.W. Genomic Profiling Reveals the Potential Role of TCL1A and MDR1 Deficiency in Chemotherapy-Induced Cardiotoxicity. Int. J. Biol. Sci. 9(4):350-360, 2013.

Mak, I.-T, Kramer, J.H., Chen X., Chmielinska, J.J, Spurney, C.F., Weglicki, W.B. Mg-supplementation Attenuates Ritonavir-induced Hyperlipidemia, Oxidative Stress and Cardiac Dysfunction in Rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 305: R1102–R1111, 2013.

Kramer J.H., Spurney, C.F., Iantorno, M., Tziros, C., Chmielinska, J.J., Mak I-T., Weglicki W.B. D-propranolol protects against oxidative stress and progressive cardiac dysfunction in Fe-overloaded rats. Can. J. Physiol. Pharmacol. 90(9):1257-68, 2012.

Weglicki, W.B., Kramer, J.H., Spurney, C.F., Chmielinska, J.J., Mak, I.T. The EGFR tyrosine kinase inhibitor tyrphostin AG-1478 causes hypomagnesemia and cardiac dysfunction. Can. J. Physiol. Pharmacol. 90(8):1145-9, 2012.

Mak, I.-T, Chmielinska, J.J, Kramer, J.H., Spurney, C.F., Weglicki, W.B. Loss Of Neutral Endopeptidase Activity Contributes To Neutrophil Activation And Cardiac Dysfunction During Chronic Hypomagnesemia: Substance P-Receptor Blockade Affords Protection. Exp. Clin. Cardiol. 16(4):121-124, 2011.

Weglicki, W.B., Chmielinska, J.J., Kramer, J.H., Mak, I-Tong. Cardiovascular and intestinal responses to oxidative and nitrosative stress during prolonged magnesium deficiency. Am. J. Med. Scis. 342(2):125-128, 2011.

Weglicki, W.B., Mak, I.-T., Chmielinska, J.J., Tejero-Taldo, M.I., Komarov, A., Kramer, J.H. The role of Magnesium Deficiency in Cardiovascular and Intestinal Inflammation. Magnes. Res. 23(4):1-8, 2010.

Mak, I. T., Chmielinska, J.J., Kramer, J.H., Weglicki. W.B. AZT-Induced Cardiovascular Toxicity - Attenuation by Mg-Supplementation. Cardiovascular Toxicol. 9:78-85, 2009.

Kramer, J.H., Spurney, C., Iantorno, M., Tziros, C., Mak, I-T., Tejero-Taldo, M.I., Chmielinska, J.J., Komarov, A.M., Weglicki, W.B. Neurogenic inflammation and cardiac dysfunction due to hypomagnesemia in a rodent model. Am. J. Med. Sci., 338:22-27, 2009.

Mak, I.T., Kramer, J.H., Chmielinska, J.J., Khalid, H., Landgraf, K., Weglicki, W.B. Inhibition of Neutral endopeptidase potentiates neutrophil activation during Mg-deficiency in the rat. Inflammation Research 57:300-305, 2008.

Kramer JH, Murthi SB, Wise RM, Mak IT, Weglicki WB. Antioxidant and lysosomotropic properties of acute d-propranolol underlies its cardioprotection of postischemic hearts from moderate iron-overloaded rats. Exp. Biol. Med. 231:473-484, 2006

Tejero-Taldo, M.I., Kramer, J.H., Mak, I-Tong, Komarov, A.M., Chmielinska, J.J., Weglicki, W.B. The nerve-heart connection in the pro-oxidant response to Mg-deficiency. Heart Failure Reviews 11:35-44, 2006.

Kramer, J.H. , Mak, I. T., Phillips, T.M., and Weglicki, W.B. Dietary Mg-intake influence circulating pro-inflammatory neuropeptide levels and loss of myocardial tolerance to postischemic stress Exp. Biol. Med. 228:665-673, 2003.

Murthi, S.B., Wise, R.M., Weglicki, W.B., Komarov, A.M., Kramer, J.H. Mg-Gluconate provides superior protection against postischemic dysfunction and oxidative injury compared to Mg-sulfate. Mole. Cell. Biochem. 245:141-148, 2003

Mak IT, Kramer JH, Weglicki WB. Suppression of neutrophil and endothelial activation by substance P receptor blockade in the Mg-deficient rat. Magne. Res. 16(2):91-97, 2003.

Additional publications published before January 1, 2013 may be available within Himmelfarb Library's database.

Industry Relationships and Collaborations

This faculty member (or a member of their immediate family) has reported a financial interest with the healthcare related companies listed below. These relations have been reported to the University and, when appropriate, management plans are in place to address potential conflicts.

  • None